发布于: 雪球转发:0回复:0喜欢:0
LM这个方向可能没有非常多的患者,但却是实实在在临床未满足的方向。这次ASCO 2024会议,伏美替尼治疗EGFR突变晚期NSCLC患者软脑膜转移(LM)的两项真实世界回顾性研究。
1.《High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study.》网页链接{Program Guide – ASCO Meeting Program Guide}
2.《The efficacy and safety of furmonertinib in patients with advanced EGFR-mutated NSCLC and leptomeningeal metastases.》网页链接{Program Guide – ASCO Meeting Program Guide}
引用:
2023-10-31 19:55
前段时间,2023ESMO上入选了一篇文章《 Efficacy and Safety of High Dose Furmonertinib Combined with Intrathecal Injection in EGFR-mutated Advanced NSCLC Patients with LM Progressed on Osimertinib 》,高剂量伏美替尼联合鞘内注射治疗奥希替尼治疗进展的伴脑转移的EGFR突变晚期NSCLC患...